Published in World J Hepatol on April 08, 2015
Ventricular repolarization measures for arrhythmic risk stratification. World J Cardiol (2016) 0.76
Electrolyte and Acid-Base Disturbances in End-Stage Liver Disease: A Physiopathological Approach. Dig Dis Sci (2017) 0.75
Prognostic Value of a New Marker of Ventricular Repolarization in Cirrhotic Patients. Arq Bras Cardiol (2016) 0.75
Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology (2010) 8.11
A G protein-coupled receptor responsive to bile acids. J Biol Chem (2003) 4.76
The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol (2013) 4.05
The cardiac output at rest in Laennec's cirrhosis. J Clin Invest (1953) 3.94
Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J (2001) 2.93
The changing role of beta-blocker therapy in patients with cirrhosis. J Hepatol (2013) 2.82
QT prolongation and sudden cardiac death in patients with alcoholic liver disease. Lancet (1993) 2.73
Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology (2005) 2.29
Electrical remodeling of the atria in congestive heart failure: electrophysiological and electroanatomic mapping in humans. Circulation (2003) 2.16
Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. Eur Heart J (2005) 1.99
Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shunts. Hepatology (2001) 1.82
Tpeak-Tend and Tpeak-Tend dispersion as risk factors for ventricular tachycardia/ventricular fibrillation in patients with the Brugada syndrome. J Am Coll Cardiol (2006) 1.78
Cirrhotic cardiomyopathy. J Am Coll Cardiol (2010) 1.77
QT interval prolongation by acute gastrointestinal bleeding in patients with cirrhosis. Liver Int (2012) 1.56
Clinical and pathologic risk factors for atherosclerosis in cirrhosis: a comparison between NASH-related cirrhosis and cirrhosis due to other aetiologies. J Hepatol (2008) 1.53
Impact of liver transplantation on rate-corrected QT interval and myocardial function in children with chronic liver disease*. Pediatr Transplant (2008) 1.48
Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology (1998) 1.39
Drug-induced QT prolongation in cirrhotic patients with transjugular intrahepatic portosystemic shunt. J Clin Gastroenterol (2011) 1.38
Liver disease selectively modulates cytochrome P450--mediated metabolism. Clin Pharmacol Ther (2006) 1.29
Does Tpeak-Tend provide an index of transmural dispersion of repolarization? Heart Rhythm (2007) 1.23
Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World J Gastroenterol (2014) 1.20
Prolongation of QTc interval: relationship with etiology and severity of liver disease, mortality and liver transplantation. Liver Int (2003) 1.17
Tp-e interval, Tp-e/QT ratio, and Tp-e/QTc ratio are prolonged in patients with moderate and severe obstructive sleep apnea. Pacing Clin Electrophysiol (2012) 1.14
Alcohol consumption and n-3 polyunsaturated fatty acids in healthy men and women from 3 European populations. Am J Clin Nutr (2008) 1.14
Brain natriuretic peptide: is it a predictor of cardiomyopathy in cirrhosis? Clin Sci (Lond) (2001) 1.08
Cardiac electrophysiological abnormalities in patients with cirrhosis. J Hepatol (2006) 1.08
Cirrhotic cardiomyopathy. Hepatol Int (2008) 1.07
Biomarkers of liver cell death. J Hepatol (2014) 1.06
Interactions of the heart and the liver. Eur Heart J (2013) 1.04
Cirrhotic cardiomyopathy. Orphanet J Rare Dis (2007) 1.03
Risk for incident atrial fibrillation in patients who receive antihypertensive drugs: a nested case-control study. Ann Intern Med (2010) 1.03
New insights into cirrhotic cardiomyopathy. Int J Cardiol (2012) 1.02
Risk indicators for out-of-hospital cardiac arrest in patients with coronary artery disease. J Clin Epidemiol (1999) 1.00
Bile acids induce arrhythmias in human atrial myocardium--implications for altered serum bile acid composition in patients with atrial fibrillation. Heart (2013) 0.99
NTproBNP: an important biomarker in cardiac diseases. Curr Top Med Chem (2013) 0.96
Effects of bile acids on ventricular muscle contraction and electrophysiological properties: studies in rat papillary muscle and isolated ventricular myocytes. Naunyn Schmiedebergs Arch Pharmacol (1987) 0.96
Cirrhotic cardiomyopathy: pathogenesis and clinical relevance. Nat Rev Gastroenterol Hepatol (2013) 0.96
Hepato-cardiac disorders. World J Hepatol (2014) 0.95
Dyssynchronous electrical and mechanical systole in patients with cirrhosis. J Hepatol (2002) 0.95
Potassium currents in atrial and ventricular myocytes from a rat model of cirrhosis. Am J Physiol (1997) 0.95
The etiology, diagnosis and prevention of liver cirrhosis: part 1 of a series on liver cirrhosis. Dtsch Arztebl Int (2013) 0.95
Cardiac dysfunction in cirrhosis is not associated with the severity of liver disease. Eur J Intern Med (2012) 0.95
QT interval prolongation and decreased heart rate variability in cirrhotic patients: relevance of hepatic venous pressure gradient and serum calcium. Clin Sci (Lond) (2009) 0.93
PR and OTc interval prolongation on the electrocardiogram after binge drinking in healthy individuals. Neth J Med (2005) 0.92
Coronary artery disease in patients with liver cirrhosis. Dig Dis Sci (2009) 0.91
QT interval analysis in patients with chronic liver disease: a prospective study. Angiology (2007) 0.91
Detection and treatment of coronary artery disease in liver transplant candidates. Liver Transpl (2001) 0.91
Torsade de pointes in liver transplantation recipient after induction of general anesthesia: a case report. Korean J Anesthesiol (2014) 0.90
Dilated cardiomyopathy associated with hepatitis C virus infection. Circulation (1995) 0.90
Alcohol, cardiac arrhythmias and sudden death. Novartis Found Symp (1998) 0.90
Infection of hepatitis B virus in extrahepatic endothelial tissues mediated by endothelial progenitor cells. Virol J (2007) 0.89
Cirrhotic cardiomyopathy. Ann Hepatol (2006) 0.88
Role of hyaluronic acid and laminin as serum markers for predicting significant fibrosis in patients with chronic hepatitis B. Braz J Infect Dis (2012) 0.87
Reversible cardiomyopathies--a review. Transplant Proc (2010) 0.87
Pharmacokinetics of erythromycin in patients with severe cirrhosis. Respective influence of decreased serum binding and impaired liver metabolic capacity. Br J Clin Pharmacol (1987) 0.87
Q-T interval prolongation in liver cirrhosis. Reversibility after orthotopic liver transplantation. Jpn Heart J (1998) 0.86
QT interval prolongation in liver cirrhosis: innocent bystander or serious threat? Expert Rev Gastroenterol Hepatol (2012) 0.85
Relationship between differential hepatic microRNA expression and decreased hepatic cytochrome P450 3A activity in cirrhosis. PLoS One (2013) 0.84
The heart: pathophysiology and clinical implications of cirrhotic cardiomyopathy. J Chin Med Assoc (2012) 0.84
Inhibitory effects of enalaprilat on rat cardiac fibroblast proliferation via ROS/P38MAPK/TGF-β1 signaling pathway. Molecules (2012) 0.83
Hepatitis C virus infection and heart diseases: a multicenter study in Japan. Jpn Circ J (1998) 0.83
Effect of cirrhosis and liver transplantation on the gender difference in QT interval. Am J Cardiol (2005) 0.83
Hypocalcemic Torsades de Pointes. J Electrocardiol (1989) 0.82
Echocardiography in liver transplant candidates. JACC Cardiovasc Imaging (2013) 0.82
The heart and the liver. Expert Rev Gastroenterol Hepatol (2009) 0.81
The effect of liver transplantation on autonomic dysfunction in patients with end-stage liver disease. Liver Transpl (2008) 0.81
Alcohol and the heart. The long-term effects of alcohol on the cardiovascular system. Arch Intern Med (1991) 0.81
Factors associated with a prolonged QT interval in liver cirrhosis patients. J Electrocardiol (2010) 0.81
CYP3A activity in severe liver cirrhosis correlates with Child-Pugh and model for end-stage liver disease (MELD) scores. Br J Clin Pharmacol (2014) 0.81
Electrophysiological properties of right heart and atrioventricular conducting system in patients with alcoholic cardiomyopathy. Br Heart J (1979) 0.81
Hepatitis B virus and myocarditis. Hum Pathol (1984) 0.81
Torsade de pointes complicating the treatment of bleeding esophageal varices: association with neuroleptics, vasopressin, and electrolyte imbalance. Am J Gastroenterol (1995) 0.80
Inflammation and atrial fibrillation: cause or para-phenomenon? Europace (2009) 0.80
Prolongation of the QTc-interval reflects the severity of autonomic neuropathy in primary biliary cirrhosis and in other non-alcoholic liver diseases. Z Gastroenterol (1993) 0.80
Prolongation of the QT interval in children with liver failure. Clin Cardiol (1999) 0.80
Drug-induced QT prolongation and sudden death. Mo Med (2010) 0.80
The Correlation between Echocardiographic Findings and QT Interval in Cirrhotic Patients. Int Cardiovasc Res J (2014) 0.80
What does the T(peak)-T(end) interval reflect? An experimental and model study. J Electrocardiol (2013) 0.79
NT pro BNP plasma level and atrial volume are linked to the severity of liver cirrhosis. PLoS One (2013) 0.79
Evaluation of Tp-e interval and Tp-e/QT ratio in patients with chronic hepatitis B. Prague Med Rep (2013) 0.79
Acute pericarditis associated with hepatitis B infection. Pediatrics (1978) 0.79
Corrected QT interval and QT dispersion in cirrhotic patients before and after liver transplantation. Arch Iran Med (2012) 0.79
Analysis of the prevalence of ventricular late potentials in the late phase of myocardial infarction based on the site of infarction. Arq Bras Cardiol (2002) 0.79
Coronary multidetector computed tomographic angiography to evaluate coronary artery disease in liver transplant candidates: methods, feasibility and initial experience. J Cardiovasc Med (Hagerstown) (2011) 0.79
Torsades de pointes triggered by severe diastolic hypotension with low hematocrit in the neohepatic stage of liver transplantation: a case report. Transplant Proc (2010) 0.78
Prevalence of pre-transplant electrocardiographic abnormalities and post-transplant cardiac events in patients with liver cirrhosis. BMC Gastroenterol (2014) 0.78
Prolonged Q-T(c) interval in mild portal hypertensive cirrhosis. J Hepatol (2005) 0.78
Impact of peri-transplant heart failure & left-ventricular diastolic dysfunction on outcomes following liver transplantation. Liver Int (2012) 0.78
Laboratory markers of ventricular arrhythmia risk in renal failure. Biomed Res Int (2014) 0.77
Q-T interval (QT(C)) in patients with cirrhosis: relation to vasoactive peptides and heart rate. Scand J Clin Lab Invest (2007) 0.77
Diurnal variation and dispersion in QT interval in cirrhosis: relation to haemodynamic changes. J Hepatol (2007) 0.77
Late ventricular potentials and heavy drinking. Heart (1997) 0.77
Statins in heart failure--With preserved and reduced ejection fraction. An update. Pharmacol Ther (2013) 0.77
[Unexpected complication following esophageal variceal hemorrhage - Case 2/2011]. Dtsch Med Wochenschr (2011) 0.77
Myocardial fibrosis and QTc are reduced following treatment with spironolactone or amiloride in stroke survivors: a randomised placebo-controlled cross-over trial. Int J Cardiol (2013) 0.76
[54-year-old male with hepatic cirrhosis and therapy-associated torsade de pointes tachycardia]. Internist (Berl) (2011) 0.76
Prolonged quinidine half-life with associated toxicity in a patient with hepatic failure. Pharmacotherapy (1997) 0.76
Liver cirrhosis prevents atrial fibrillation: A reality or just an illusion? J Cardiovasc Dis Res (2012) 0.76